These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31633158)

  • 1. Lopinavir-Ritonavir Impairs Adrenal Function in Infants.
    Kariyawasam D; Peries M; Foissac F; Eymard-Duvernay S; Tylleskär T; Singata-Madliki M; Kankasa C; Meda N; Tumwine J; Mwiya M; Engebretsen I; Flück CE; Hartmann MF; Wudy SA; Hirt D; Treluyer JM; Molès JP; Blanche S; Van De Perre P; Polak M; Nagot N;
    Clin Infect Dis; 2020 Aug; 71(4):1030-1039. PubMed ID: 31633158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
    Foissac F; Blume J; Tréluyer JM; Tylleskär T; Kankasa C; Meda N; Tumwine JK; Singata-Madliki M; Harper K; Illamola SM; Bouazza N; Nagot N; Van de Perre P; Blanche S; Hirt D
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
    Nagot N; Kankasa C; Tumwine JK; Meda N; Hofmeyr GJ; Vallo R; Mwiya M; Kwagala M; Traore H; Sunday A; Singata M; Siuluta C; Some E; Rutagwera D; Neboua D; Ndeezi G; Jackson D; Maréchal V; Neveu D; Engebretsen IMS; Lombard C; Blanche S; Sommerfelt H; Rekacewicz C; Tylleskär T; Van de Perre P;
    Lancet; 2016 Feb; 387(10018):566-573. PubMed ID: 26603917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
    Simon A; Warszawski J; Kariyawasam D; Le Chenadec J; Benhammou V; Czernichow P; Foissac F; Laborde K; Tréluyer JM; Firtion G; Layouni I; Munzer M; Bavoux F; Polak M; Blanche S;
    JAMA; 2011 Jul; 306(1):70-8. PubMed ID: 21730243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
    N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
    Nagot N; Kankasa C; Meda N; Hofmeyr J; Nikodem C; Tumwine JK; Karamagi C; Sommerfelt H; Neveu D; Tylleskär T; Van de Perre P;
    BMC Infect Dis; 2012 Oct; 12():246. PubMed ID: 23039034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
    Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N;
    Lancet HIV; 2019 May; 6(5):e307-e314. PubMed ID: 30814028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T; Bowonwattanuwong C; Jirajariyavej S; Munsakul W; Klinbuayaem V; Sophonphan J; Mahanontharit A; Hirschel B; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2014; 19(6):579-86. PubMed ID: 24464590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
    Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
    Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
    Nagot N; Singata-Madliki M; Cournil A; Nalugya J; Tassembedo S; Quillet C; Tonga MW; Tumwine J; Meda N; Kankasa C; Mwiya M; Bangirana P; Peries M; Batting J; Engebretsen IMS; Tylleskär T; Perre PV; Ndeezi G; Molès JP
    Sci Rep; 2021 Feb; 11(1):3173. PubMed ID: 33542437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
    Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
    Jacobs TG; Mumbiro V; Chitsamatanga M; Namuziya N; Passanduca A; Domínguez-Rodríguez S; Tagarro A; Nathoo KJ; Nduna B; Ballesteros A; Madrid L; Mujuru HA; Chabala C; Buck WC; Rojo P; Burger DM; Moraleda C; Colbers A; ;
    J Acquir Immune Defic Syndr; 2023 May; 93(1):42-46. PubMed ID: 36724434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
    McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
    Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
    Kolta S; Flandre P; Van PN; Cohen-Codar I; Valantin MA; Pintado C; Morlat P; Boué F; Rode R; Norton M; Knysz B; Briot K; Roux C; Delfraissy JF
    Curr HIV Res; 2011 Jan; 9(1):31-9. PubMed ID: 21198431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
    Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
    HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.